{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:56:51Z","timestamp":1793213811629,"version":"4.5.0"},"reference-count":59,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13196","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:18:48Z","timestamp":1780057128000},"page":"1-12","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing management of immune checkpoint inhibitor\u2011induced inflammatory arthritis: A case series and literature review"],"prefix":"10.3892","volume":"32","author":[{"given":"Yuanyuan","family":"Wang","sequence":"first","affiliation":[{"name":"Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430065, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmei","family":"Wen","sequence":"additional","affiliation":[{"name":"Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430065, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxiong","family":"Xia","sequence":"additional","affiliation":[{"name":"Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430065, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Feng","sequence":"additional","affiliation":[{"name":"Positron Emission Tomography\u2011Computed Tomography\/Magnetic Resonance Imaging Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. Chin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafu","family":"Ye","sequence":"additional","affiliation":[{"name":"Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430065, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430065, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430065, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yao","sequence":"additional","affiliation":[{"name":"Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430065, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"key20260715092703_b1-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"key20260715092703_b2-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drudis.2019.11.003","article-title":"Immune checkpoint inhibitors: A promising anticancer therapy","volume":"25","author":"Singh","year":"2020","journal-title":"Drug Discov Today"},{"issue":"1167975","key":"key20260715092703_b3-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: A review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"key20260715092703_b4-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of Immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"804597","key":"key20260715092703_b5-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto","year":"2022","journal-title":"Front Immunol"},{"key":"key20260715092703_b6-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/rheumatology\/keae343","article-title":"Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: A retrospective cohort study","volume":"64","author":"Bass","year":"2024","journal-title":"Rheumatology"},{"key":"key20260715092703_b7-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"e36334","key":"key20260715092703_b8-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036334","article-title":"Immune checkpoint inhibitor induced colitis and arthritis: A case report","volume":"102","author":"Xie","year":"2023","journal-title":"Medicine"},{"key":"key20260715092703_b9-ETM-32-2-13196"},{"issue":"S806","key":"key20260715092703_b10-ETM-32-2-13196","article-title":"564P Efficacy and safety of tislelizumab plus anlotinib in the treatment of cervical cancer resistant to standard therapy: A prospective, single-arm, open labelled phase II clinical trial","volume":"33 (Suppl)","author":"Zheng","year":"2022","journal-title":"Ann Oncol"},{"issue":"e200032","key":"key20260715092703_b11-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0032","article-title":"Use of magnetic resonance imaging to identify immune checkpoint inhibitor-induced inflammatory arthritis","volume":"3","author":"Subedi","year":"2020","journal-title":"JAMA Netw Open"},{"key":"key20260715092703_b12-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58 (Suppl 7)","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatology"},{"issue":"3389","key":"key20260715092703_b13-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093389","article-title":"Rheumatic manifestations in patients treated with immune checkpoint inhibitors","volume":"21","author":"Melissaropoulos","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20260715092703_b14-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58 (Suppl 7)","author":"Kostine","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"key20260715092703_b15-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/acr.23467","article-title":"Arthritis after cancer immunotherapy: Symptom duration and treatment response","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res"},{"key":"key20260715092703_b16-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: A single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"key20260715092703_b17-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260715092703_b18-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"888377","key":"key20260715092703_b19-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.888377","article-title":"Clinical patterns and follow-up of inflammatory arthritis and other immune-related adverse events induced by checkpoint inhibitors. A multicenter study","volume":"9","author":"G\u00f3mez-Puerta","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"key20260715092703_b20-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"e010758","key":"key20260715092703_b21-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010758","article-title":"Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells","volume":"13","author":"Paiola","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"74","key":"key20260715092703_b22-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03546-3","article-title":"Higher levels of VEGF-A and TNF\u03b1 in patients with immune checkpoint inhibitor-induced inflammatory arthritis","volume":"27","author":"Gray-Gaillard","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"key20260715092703_b23-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.14336\/AD.2024.0546","article-title":"The roles of T cells in immune checkpoint inhibitor-induced arthritis","volume":"16","author":"Chen","year":"2024","journal-title":"Aging Dis"},{"issue":"eadd1591","key":"key20260715092703_b24-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add1591","article-title":"Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis","volume":"8","author":"Wang","year":"2023","journal-title":"Sci Immunol"},{"issue":"2107","key":"key20260715092703_b25-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46195-x","article-title":"Single-cell profiling identifies IL1Bhi macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat Commun"},{"issue":"535784","key":"key20260715092703_b26-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.535784","article-title":"The antigen presenting potential of CD21low B cells","volume":"11","author":"Reincke","year":"2020","journal-title":"Front Immunol"},{"key":"key20260715092703_b27-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"key20260715092703_b28-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/art.42406","article-title":"Early increase of circulating transitional B Cells and autoantibodies to joint-related proteins in patients with metastatic melanoma developing checkpoint inhibitor-induced inflammatory arthritis","volume":"75","author":"Gatto","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"key20260715092703_b29-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1634\/theoncologist.2016-0390","article-title":"Inflammatory arthritis: A newly recognized adverse event of immune checkpoint blockade","volume":"22","author":"Naidoo","year":"2017","journal-title":"Oncologist"},{"issue":"e9","key":"key20260715092703_b30-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"key":"key20260715092703_b31-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"key20260715092703_b32-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"102455","key":"key20260715092703_b33-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garc\u00eda","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"5126717","key":"key20260715092703_b34-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5126717","article-title":"The terrible triad of checkpoint inhibition: A case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Reports Immunol"},{"issue":"103943","key":"key20260715092703_b35-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103943","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis vs rheumatoid arthritis: A comparative review","volume":"25","author":"Georgios","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"e176567","key":"key20260715092703_b36-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176567","article-title":"Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures","volume":"134","author":"Kao","year":"2025","journal-title":"J Clin Invest"},{"issue":"e227995","key":"key20260715092703_b37-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-227995","article-title":"Immune checkpoint inhibitor-induced rheumatoid arthritis: Insights into an increasingly common aetiology of polyarthritis","volume":"12","author":"Kwok","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"100434","key":"key20260715092703_b38-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejro.2022.100434","article-title":"Imaging features of toxicities associated with immune checkpoint inhibitors","volume":"9","author":"Gosangi","year":"2022","journal-title":"Eur J Radiol Open"},{"key":"key20260715092703_b39-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1007\/s10067-020-05162-9","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: A novel clinical entity with striking similarities to seronegative rheumatoid arthritis","volume":"39","author":"Liu","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"1961","key":"key20260715092703_b40-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081961","article-title":"Imaging findings in patients with immune checkpoint inhibitor-induced arthritis","volume":"12","author":"Ponce","year":"2022","journal-title":"Diagnostics"},{"issue":"1990","key":"key20260715092703_b41-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16111990","article-title":"Is 18F-FDG-PET\/CT an optimal imaging modality for detecting immune-related adverse events after immune-checkpoint inhibitor therapy?","volume":"16","author":"Karlsen","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"e002435","key":"key20260715092703_b42-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key20260715092703_b43-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260715092703_b44-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"key20260715092703_b45-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"867","DOI":"10.55563\/clinexprheumatol\/e49am5","article-title":"Clinical outcomes in cancer patients with immune checkpoint inhibitor-induced arthritis treated with methotrexate: A retrospective longitudinal monocentric pilot study","volume":"43","author":"Hysa","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"key20260715092703_b46-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"key20260715092703_b47-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","article-title":"Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: The TAPIR study","volume":"36","author":"Petit","year":"2025","journal-title":"Ann Oncol"},{"issue":"e28428","key":"key20260715092703_b48-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028428","article-title":"Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report","volume":"101","author":"Abe","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"key20260715092703_b49-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2217\/imt-2021-0274","article-title":"Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy","volume":"14","author":"Ma","year":"2022","journal-title":"Immunotherapy"},{"issue":"803","key":"key20260715092703_b50-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05617-6","article-title":"Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: A multi-center observational study","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"issue":"e238851","key":"key20260715092703_b51-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-238851","article-title":"First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis","volume":"14","author":"Murray","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"e003551","key":"key20260715092703_b52-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003551","article-title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: From monoclonal antibodies to kinase inhibition","volume":"10","author":"Berg","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key20260715092703_b53-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"6991","DOI":"10.1007\/s12274-022-5275-5","article-title":"Native and engineered exosomes for inflammatory disease","volume":"16","author":"Ma","year":"2023","journal-title":"Nano Res"},{"key":"key20260715092703_b54-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: A single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1759720X211006963","key":"key20260715092703_b55-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211006963","article-title":"Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: A single-centre analysis","volume":"13","author":"Verspohl","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"105795","key":"key20260715092703_b56-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105795","article-title":"Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study","volume":"92","author":"Ladouceur","year":"2025","journal-title":"Joint Bone Spine"},{"key":"key20260715092703_b57-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: Management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"key20260715092703_b58-ETM-32-2-13196","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2217\/imt-2020-0103","article-title":"Outcomes following immunotherapy re-challenge after immune-related adverse event: Systematic review and meta-analysis","volume":"12","author":"Park","year":"2020","journal-title":"Immunotherapy"},{"issue":"e003795","key":"key20260715092703_b59-ETM-32-2-13196","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003795","article-title":"Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: A multicentre observational study","volume":"9","author":"Ladouceur","year":"2023","journal-title":"RMD Open"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:27:08Z","timestamp":1784096828000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,29]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13196","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}